𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Negative opinion from the CHMP for biosimilar interferon-α

Book ID
120851374
Publisher
Adis International Limited (now part of Wolters Kluwer Health)
Year
2006
Weight
133 KB
Volume
&NA;
Category
Article
ISSN
1173-8324

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Practical guidelines for the management
Practical guidelines for the management of interferon-α-2b side effects in patients receiving adjuvant treatment for melanoma : Expert opinion
✍ Axel Hauschild; Helen Gogas; Ahmad Tarhini; Mark R. Middleton; Alessandro Testor 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB

## Abstract Interferon‐α‐2b (IFNα2b) is the only effective adjuvant therapy for melanoma patients at high risk of recurrence that has been approved by regulatory authorities worldwide. However, IFN toxicities increase the risk of poor treatment compliance and impair the potential for benefit from t

Insights from interferon-α-related depre
Insights from interferon-α-related depression for the pathogenesis of depression associated with inflammation
✍ Hoyo-Becerra, Carolina; Schlaak, Joerg F.; Hermann, Dirk M. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 807 KB

Interferon-α (IFN-α) is a pleiotropic cytokine that is administered as a therapeutic in highly prevalent medical conditions such as chronic hepatitis C and B virus infection, melanoma and lymphoma. IFN-α induces, to a clinically relevant degree, concentration, memory, drive and mood disturbances in